{"entity":{"id":"forward-pharmaceuticals","kind":"company","name":"Forward Pharmaceuticals","aka":["Forward Pharmaceuticals Co., Ltd."],"tldr":"Forward Pharmaceuticals is a China-based biotechnology company running 2 late-stage cancer trials of FWD1802 in HR-positive / HER2-negative breast cancer.","summary":"Forward Pharmaceuticals, based in Shenzhen, China, is a biotechnology company. Forward Pharma is a clinical-stage biotechnology company focused exclusively on oncology drug development, using structural characterisation, biophysical profiling and computational optimisation. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials, testing FWD1802 in HR-positive / HER2-negative breast cancer. The largest, NCT07002177 (A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC), plans to enrol 196 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.forward-pharm.com"},{"label":"ClinicalTrials.gov: trials led by Forward Pharmaceuticals","url":"https://clinicaltrials.gov/search?lead=Forward%20Pharmaceuticals%20Co.%2C%20Ltd."},{"label":"Pipeline page","url":"https://www.forward-pharm.com/pipeline"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["breast-hr-positive"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["pivotal-trial","clinical-trial"],"trials":["nct07002177","nct06064812"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Shenzhen","country":"CN","companyType":"biotech","website":"https://www.forward-pharm.com","founded":2015,"stage":"growth","investors":[],"funding":[]},"route":"/companies/forward-pharmaceuticals/","neighbours":{"cancer":[{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"}],"term":[{"id":"clinical-trial","kind":"term","name":"Clinical trial","route":"/terms/clinical-trial/"},{"id":"pivotal-trial","kind":"term","name":"Pivotal (registrational) trial","route":"/terms/pivotal-trial/"}],"trial":[{"id":"nct06064812","kind":"trial","name":"A Phase I/II Study of FWD1802 in Patients With ER+/HER2- Advanced BC.","route":"/trials/nct06064812/"},{"id":"nct07002177","kind":"trial","name":"A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC","route":"/trials/nct07002177/"}]}}